Clin2
NCT01306019Possibly a fitRecruiting

Gene therapy for children with severe immune deficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)

Treatments studied

Part of Genetic & congenital, Immune system & allergy clinical trials.

This trial tests a one-time gene therapy approach to help children with X-linked SCID (a serious inherited immune disorder) make better immune cells. It’s for people who don’t have a fully matched sibling donor and need long-term follow-up after treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
40 people
Ages
2 years to 50 years
Study type
Interventional

Who can take part

  • You have a confirmed XSCID-causing genetic change in the common gamma chain gene (from a DNA test).
  • You have no fully tissue-typed matched sibling donor available.
  • You are age 2 to 50, and you weigh at least 10 kg (about 22 lb).
  • If you had a transplant before, it must be at least 18 months ago.
  • You must be able to store blood and tissue samples for the study, and your doctor must feel your home/social situation will let you complete the study and long-term follow-up.
  • You must have signs of severe immune weakness (for example very low immunity proteins like IgG, or needing regular IVIG) plus either lab signs (like very low CD4/T-cells or low immune cell numbers) or clinical signs (like frequent significant infections or chronic lung/GI problems).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06851767Enrolling by invitation· Phase 1/Phase 2
Gene therapy for X-linked severe combined immunodeficiency

This trial tests a gene therapy that uses base-edited stem cells to treat X-SCID, a genetic immune disorder. It may help improve immune function and reduce infections in patients who still have low immune cells or severe infections despite previous treatments.

Bethesda, Maryland
NCT07113743Enrolling by invitation· Phase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease

This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.

Bethesda, Maryland
NCT06959771Recruiting· Phase 1/Phase 2
Gene therapy for CD40L deficiency (Hyper-IgM syndrome) - single patient study

This trial tests a new gene therapy that uses a person's own blood stem cells and T cells, which are corrected with a gene-editing tool called base editing. It is designed for people with a specific CD40L gene mutation who also have liver problems and portal hypertension. The goal is to see if this treatment can improve their immune system and liver health.

Bethesda, Maryland
NCT06325709Recruiting· Phase 1/Phase 2
Gene editing trial for X-linked chronic granulomatous disease

This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.

Bethesda, Maryland
NCT04339777Recruiting· Phase 2
Bone marrow transplant for inherited immune system disorders

This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.

Bethesda, Maryland
NCT07775313Not yet recruiting· Phase 1/Phase 2
Gene therapy for WHIM syndrome

This trial tests a one-time gene therapy treatment for WHIM syndrome, a rare immune disorder. It aims to fix the genetic cause to improve your body's ability to fight infections. Your stem cells will be collected, edited in a lab, and given back to you after some chemotherapy to prepare your body.

Bethesda, Maryland

Hear when a new X-linked Severe Combined Immunodeficiency (XSCID) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.